Skip to Content

Trodelvy Side Effects

Generic name: sacituzumab govitecan

Medically reviewed by Last updated on May 11, 2020.

Note: This document contains side effect information about sacituzumab govitecan. Some of the dosage forms listed on this page may not apply to the brand name Trodelvy.

For the Consumer

Applies to sacituzumab govitecan: intravenous powder for injection


Sacituzumab govitecan affects your immune system. You may get infections more easily, even serious or fatal infections. Tell your doctor if you have a fever, chills, pain or burning when you urinate, cough, or trouble breathing.

Sacituzumab govitecan commonly causes diarrhea. Severe diarrhea can lead to dehydration, which may require medical treatment.

Tell your doctor right away the first time you have diarrhea while receiving this medicine, or if you have black or bloody stools, if you feel light-headed, if you can't keep liquids down because of vomiting, or if you can't get your diarrhea to stop within 24 hours.

This medicine can cause severe or life-threatening allergic reactions.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection or within 24 hours afterward. Tell your caregiver if you feel dizzy, light-headed, itchy, sweaty, or have a fever, chills, trouble breathing, or swelling in your face or throat.

You may get infections more easily, even serious or fatal infections. Call your doctor right away if you have:

  • pain or burning when you urinate;

  • low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or

  • low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough, trouble breathing.

Sacituzumab govitecan (the active ingredient contained in Trodelvy) can cause severe diarrhea. Tell your doctor right away if you have:

  • diarrhea (the first time it occurs);

  • diarrhea lasting longer than 24 hours (even if you use anti-diarrhea medicine);

  • black or bloody stools;

  • severe or ongoing vomiting, especially if you can't keep liquids down; or

  • a light-headed feeling, like you might pass out.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to sacituzumab govitecan: intravenous powder for injection


Very common (10% or more): Hemoglobin decreased (93%), leukocytes decreased (91%), neutropenia (83%), activated partial thromboplastin time increased (60%), anemia (52%), platelets decreased (30%), thrombocytopenia (14%)[Ref]


Frequency not reported: Immunogenicity


Very common (10% or more): Back pain (23%), arthralgia (17%), pain in extremity (11%)[Ref]


Very common (10% or more): Alkaline phosphatase increased (57%), magnesium decreased (51%), calcium decreased (49%), glucose increased (48%), aspartate aminotransferase increased (45%), albumin decreased (39%), alanine aminotransferase increased (35%), anorexia (30%), potassium decreased (30%), sodium decreased (25%), hyperglycemia (24%), hypomagnesemia (24%), hypokalemia (19%), glucose decreased (19%), hypophosphatemia (16%), dehydration (13%)[Ref]


Very common (10% or more): Insomnia (13%)[Ref]


Very common (10% or more): Urinary tract infection (21%)[Ref]


Very common (10% or more): Respiratory infection (e.g., lower and upper respiratory tract infection, pneumonia, influenza, viral upper respiratory infection, bronchitis, respiratory syncytial virus infection) (26%), cough/productive cough (22%), dyspnea/exertional dyspnea (21%)[Ref]


Very common (10% or more): Fatigue/asthenia (57%), edema (e.g., peripheral, localized, periorbital) (19%), pyrexia (14%)[Ref]


The most frequent serious adverse reactions (reported in greater than 1%) of patients were febrile neutropenia (6%) vomiting (5%), nausea (3%), dyspnea (3%), diarrhea (4%), anemia (2%), pleural effusion, neutropenia, pneumonia, and dehydration.[Ref]

Nervous system

Very common (10% or more): Headache (23%), dizziness (22%), neuropathy (e.g., gait disturbance, hypoesthesia, muscular weakness, paresthesia, peripheral neuropathy, sensory neuropathy) (24%), dysgeusia (11%)[Ref]


Very common (10% or more): Alopecia (38%), rash (e.g., maculopapular, erythematous, generalized rash, dermatitis acneiform, skin disorder, irritation, exfoliation) (31%), pruritus (17%), dry skin (15%)[Ref]


Very common (10% or more): Nausea (69%), diarrhea (63%), vomiting (49%), constipation (34%), abdominal pain (e.g., abdominal pain, distention, upper abdominal pain, discomfort, tenderness) (26%), mucositis (e.g., stomatitis, esophagitis, mucosal inflammation) (14%)[Ref]


1. "Product Information. Trodelvy (sacituzumab govitecan)." Immunomedics, Morris Plains, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.